Physician profile
Allison Cassetta
NPI 1467917211
$6,988.81
in general payments reported to CMS, 2019-2025
27 companies · $3,536 in 2025
The $3,536 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $534 · 2022: $369 · 2023: $239 · 2024: $2,310 · 2025: $3,536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,069 · Education: $16.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,069.11 |
| Education | $16.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,642.61 | 2021-2025 | |
| Gilead Sciences, INC. | $1,024.61 | 2021-2025 | Livdelzi |
| Janssen Biotech, INC. | $571.92 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $554.22 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $468.87 | 2022-2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $439.71 | 2024-2025 | Dupixent |
| Ardelyx, INC. | $380.13 | 2024-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $237.11 | 2024-2025 | Rezdiffra, Resmetirom |
| Enterra Medical, INC. | $221.84 | 2022-2025 | |
| Lilly USA, LLC | $219.19 | 2024-2025 | Omvoh, Zepbound |
| Regeneron Pharmaceuticals, INC. | $214.71 | 2025 | Dupixent |
| Genzyme Corporation | $211.90 | 2023-2025 | |
| Qol Medical, LLC | $187.98 | 2024-2025 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $130.19 | 2024-2025 | Zenpep |
| Pfizer INC. | $105.87 | 2021-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $69.79 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $51.71 | 2024-2025 | Rebyota |
| Redhill Biopharma INC. | $49.27 | 2021-2022 | |
| Organon LLC | $41.24 | 2024-2025 | Renflexis, Hadlima |
| Celgene Corporation | $31.20 | 2023-2024 | Zeposia |
| Axonics, INC. | $22.00 | 2024 | Bulkamid, Axonics |
| Ipsen Biopharmaceuticals, INC | $21.20 | 2025 | Iqirvo |
| Mirum Pharmaceuticals, INC. | $21.12 | 2025 | Livmarli |
| Ironwood Pharmaceuticals, INC | $19.77 | 2024 | |
| Phathom Pharmaceuticals, INC. | $19.17 | 2024 | Voquezna |
| Celltrion USA INC. | $16.17 | 2024 | Zymfentra |
| Endogastric Solutions, INC | $15.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Cassetta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.